[Clinical application of NK 631 to head-and-neck cancers (author's transl)].
NK 631, a new antibiotic of bleomycin analogue, was applied to the treatment of 15 patients with head-and-neck cancers. The results obtained were slightly better than bleomycin-treated cases. For the side effect of NK 631, there were no lung disorders in all patients.
D000368:Aged; D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D001761:Bleomycin